Chronic cough is a persistent cough that lasts for eight weeks or longer in adults and is often a symptom of underlying respiratory or non-respiratory conditions. Common causes include asthma, gastroesophageal reflux disease (GERD), upper airway cough syndrome, chronic obstructive pulmonary disease (COPD), and certain medications.

Chronic Cough Market Size, Share and Analysis

The chronic cough market is on a trajectory of substantial growth, with projections indicating an increase from US$ 7.23 billion in 2021 to US$ 13.60 billion by 2031. This growth reflects a compound annual growth rate (CAGR) of 8.2% during the period from 2023 to 2031. The expansion of this market is primarily driven by rising awareness of respiratory disorders, advancements in medical research, and the ongoing trend of drug development.

Market Analysis

The global chronic cough market is significantly influenced by the rising prevalence of chronic lung infections, as persistent cough is a common symptom. The market's expansion is supported by a growing focus on respiratory health and wellness, along with various government and non-government initiatives aimed at improving patient care.

Overview of Chronic Cough

A chronic cough is defined as a cough that persists for eight weeks or longer. It can result from various conditions, including infections, asthma, and gastroesophageal reflux disease. Symptoms associated with chronic cough include postnasal drip, headaches, throat irritation, hoarseness, shortness of breath, wheezing, and heartburn. Increased investments in healthcare infrastructure, diagnostic facilities, and patient education programs are enhancing the management and early detection of chronic cough.

Drivers and Opportunities

Growing Adoption of Chronic Cough Treatments

Conditions such as infections, lung diseases, and bronchitis are significant contributors to the prevalence of chronic cough. The rise in asthma cases globally, particularly among children and adults, is noteworthy. According to a study published in February 2024, the prevalence of chronic cough varies between 2% and 18% across different populations. Contributing factors include smoking, obesity, chronic obstructive pulmonary disease (COPD), and gastroesophageal reflux disease (GORD).

Rising Aging Population

The increasing aging population is expected to drive demand for chronic cough treatments. Older individuals are more susceptible to chronic cough due to decreased immunity and the degeneration of healthy tissues. As people age, the respiratory system becomes more vulnerable to infections such as pneumonia and influenza. The World Health Organization projects that by 2050, the global population aged 60 and above will reach 2.1 billion, significantly increasing the demand for chronic cough treatments.

Get Sample Report: https://www.theinsightpartners.com/sample/TIPRE00011584

Market Segmentation Analysis

• Drug Class: The market is categorized into antihistamines, corticosteroids, decongestants, combination drugs, antibiotics, acid blockers, and other classes. The combination drug segment held the largest market share in 2023.
• Route of Administration: This includes oral, injections, inhalation, and other methods, with the oral segment dominating the market in 2023.
• Distribution Channel: The market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacy segment led the market in 2023.

North America

North America has emerged as a leading region in the chronic cough market. The demand for over-the-counter (OTC) products is a significant factor driving revenue growth in this region. Additionally, the increasing incidence of chronic cough, a rapidly growing elderly population, and rising vehicle pollution contribute to the heightened demand for cough remedy products.

Key Players

• Novartis AG
• Teva Pharmaceutical Industries Ltd
• GlaxoSmithKline plc
• Bayer AG
• Mylan N.V.
• Amneal Pharmaceuticals Inc
• Cipla Inc
• Reckitt Benckiser Group plc
• Sun Pharmaceutical Industries Ltd
• Aurobindo Pharma Ltd

Future Outlook

The chronic cough market is anticipated to experience robust growth as healthcare priorities continue to shift toward respiratory health. Innovations in treatment options and increasing public awareness will further drive market expansion. With the aging population and the rising prevalence of respiratory diseases, stakeholders in the chronic cough market must focus on developing targeted therapies and ensuring patient access to effective medications. Collaborative efforts between pharmaceutical companies, healthcare providers, and policymakers will be essential in addressing the growing demand for chronic cough treatments, ultimately enhancing patient outcomes and quality of life.

FAQ:

 Q1. What is chronic cough?
Chronic cough is a cough that lasts more than 8 weeks in adults and more than 4 weeks in children, often indicating an underlying medical condition.

Q2. What are the common causes of chronic cough?
Common causes include asthma, GERD (acid reflux), upper airway cough syndrome (postnasal drip), COPD, smoking, air pollution exposure, and certain medications such as ACE inhibitors.

Q3. How is chronic cough diagnosed?
Diagnosis typically involves medical history review, physical examination, chest imaging, lung function tests, and sometimes allergy or reflux evaluations to identify the root cause.

Also Available in: Korean|German|Japanese|French|Chinese|Italian|Spanish